UroGen Pharma (URGN) Change in Accured Expenses (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Change in Accured Expenses data on file, last reported at $7.6 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 311.74% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (up 8.07% YoY) and the FY2025 annual result came in at $2.9 million, down 72.96% from the prior year.
• Change in Accured Expenses rose to $7.6 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $13.0 million in Q2 2024 to a low of -$5.8 million in Q1 2024.
• A 5-year average of $1.6 million and a median of $708000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 427.68% — and 2024, when it jumped 1894.36%.
• Tracing URGN's Change in Accured Expenses over 5 years: stood at $4.1 million in 2022, then slumped by 39.46% to $2.5 million in 2023, then surged by 215.52% to $7.7 million in 2024, then sank by 45.73% to $4.2 million in 2025, then soared by 81.47% to $7.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $7.6 million (Q1 2026), $4.2 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.